# Brian G. Feagan

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/brian-g-feagan/

## Facts

| Field | Value |
| --- | --- |
| Citations | 91,864 |
| Field | Inflammatory Bowel Disease |
| h-index | 137 |
| i10-index | 521 |
| Last Known Institution | Western University |
| OpenAlex ID | https://openalex.org/A5048464948 |
| ORCID iD | https://orcid.org/0000-0002-6914-3822 |
| Works | 1,252 |

## Researcher papers

Showing 12 of 14.

- [Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis](https://scholariq.org/papers/vedolizumab-as-induction-and-maintenance-therapy-for-ulcerative-colitis/)
- [Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target](https://scholariq.org/papers/selecting-therapeutic-targets-in-inflammatory-bowel-disease-stride-determining/)
- [Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease](https://scholariq.org/papers/ustekinumab-as-induction-and-maintenance-therapy-for-crohn-s-disease/)
- [Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis](https://scholariq.org/papers/tofacitinib-as-induction-and-maintenance-therapy-for-ulcerative-colitis/)
- [Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial](https://scholariq.org/papers/secukinumab-a-human-anti-il-17a-monoclonal-antibody-for-moderate-to-severe-crohn/)
- [SCENIC International Consensus Statement on Surveillance and Management of Dysplasia in Inflammatory Bowel Disease](https://scholariq.org/papers/scenic-international-consensus-statement-on-surveillance-and-management-of-2/)
- [Development of the Crohnʼs disease digestive damage score, the Lémann score](https://scholariq.org/papers/development-of-the-crohn-s-disease-digestive-damage-score-the-lemann-score/)
- [SCENIC international consensus statement on surveillance and management of dysplasia in inflammatory bowel disease](https://scholariq.org/papers/scenic-international-consensus-statement-on-surveillance-and-management-of/)
- [Effects of Adalimumab Therapy on Incidence of Hospitalization and Surgery in Crohn's Disease: Results From the CHARM Study](https://scholariq.org/papers/effects-of-adalimumab-therapy-on-incidence-of-hospitalization-and-surgery-in/)
- [Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn’s Disease After Ileocolonic Resection](https://scholariq.org/papers/infliximab-reduces-endoscopic-but-not-clinical-recurrence-of-crohn-s-disease/)
- [Treatment of Active Crohn's Disease With MLN0002, a Humanized Antibody to the α4β7 Integrin](https://scholariq.org/papers/treatment-of-active-crohn-s-disease-with-mln0002-a-humanized-antibody-to-the-4-7/)
- [Pharmacokinetics and Exposure Response Relationships of Ustekinumab in Patients With Crohn's Disease](https://scholariq.org/papers/pharmacokinetics-and-exposure-response-relationships-of-ustekinumab-in-patients/)

## Researcher topics

- [Inflammatory Bowel Disease](https://scholariq.org/topics/inflammatory-bowel-disease/)
- [Microscopic Colitis](https://scholariq.org/topics/microscopic-colitis/)
- [Autoimmune and Inflammatory Disorders](https://scholariq.org/topics/autoimmune-and-inflammatory-disorders/)
- [Rheumatoid Arthritis Research and Therapies](https://scholariq.org/topics/rheumatoid-arthritis-research-and-therapies/)
- [Eosinophilic Esophagitis](https://scholariq.org/topics/eosinophilic-esophagitis/)

## Researcher university

- [Western University](https://scholariq.org/institutions/western-university/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.